Introduction
CiMaas develops immunotherapy for cancer by optimally engaging the immune system.
Read more about CiMaas Immunotherapy products,
or watch our video.
CiMaas is successful in expanding Natural Killer cells obtained from a small population in peripheral blood into very high numbers in just 2 weeks. This is directly applicable for clinical application in anti-cancer therapy.
Cimaas has received an important stimulus from the Netherlands Enterprise Agency (RVO) for the development of a therapeutic dendritic cell (DC) vaccine against lung cancer. It concerns a loan of € 2.4 million.
As of October 1, 2020 esteemed tumor immunologist Prof Dr Jolanda de Vries becomes a member of the scientific advisory board. Jolanda de Vries is head of the department of Tumor Immunology at Radboudumc, Nijmegen, the Netherlands.